The New York Stock Exchange with a Hims & Hers Health banner is represented in the Manhattan borough of New York.
Carlo Allegri | Reuters
Hims & His Health Announced Wednesday that it acquired the installation of home laboratory tests based in New Jersey, Trybe Labs.
The agreement will allow the Télésanté company to offer blood blood pressure samples and more complete pre -treatment tests to its users.
“Access to richer data allows us to deepen the ideas that providers can use on our platform to guide their clinical decisions for each individual patient,” said Dr. Patrick Carroll, chief of Hims & Hers.
“Home laboratory tests are an increasingly exciting step towards raising personal and complete customers in this country should expect,” added Dr. Carroll.
Hims & Hers did not disclose the conditions of the agreement, but said that it had funded it by cash. The company has told CNBC that it will share prices for new test options when the offer will be made available to customers over the next year.
The acquisition of Hims & Hers will offer competition to blood drawing services such as Labcorp and Quest Diagnostics.
The startup extends its services less than a year after starting to offer compound GLP-1 weight loss medications. As Hims and his presents himself as a cheaper alternative to established companies, he recently targeted the pharmaceutical industry in an announcement of the Super Bowl, saying that the industry is “at the cost of profits, not patients”.
“The health care that customers are waiting for and deserve today are on -demand care with treatments specially designed for them,” said Dr. Carroll.
Friday, the company announced separately having acquired a peptide installation based in the United States in California as part of its last expansion of this interior supply chain.
“A large part of the demand for peptides is faced with innovation,” Andrew Dudum, Hims & Hers Health said on Friday after this announcement. “So much use cases have not yet been launched,” he added.
The acquisition follows previous purchases of drug manufacturing facilities in Ohio and Arizona in the past six years.
Although Hims did not reveal the international exhibition of its supply chain, Dudum stressed that this agreement comes at a time when the Trump administration represses the dependence of the broader pharmaceutical industry with regard to the production abroad.
Peptide therapy has gained popularity in recent years, especially within the fitness and well-being community. The Secretary of Health and Social Services Robert F. Kennedy Jr. vocalized the support of treatment as an alternative medicine, saying that it was under the “aggressive abolition” by the Food and Drug Administration as other alternatives like Psychedelics, stem cells and raw milk.
However, excitement surrounding peptide innovations has limited scientific evidence supporting their long -term advantages.
DUDUM said the acquisition will allow its business to explore areas, including recovery science, preventive health and rejuvenation.
“Peptide innovation is at the forefront of so many categories that we are delighted to start offering,” said Dudum.
Acquisition of Trybe
The acquisition of Hims & Hers of Trybe Labs will add test capacities for LDL cholesterol, lipoprotein (A), cholesterol and apolipoprotein, said the company. It will also expand the company’s ability to offer access to care and treatments in a range of conditions, including low testosterone and perimeneopausic and menopausic support.
The Tasso + device is a blood lancet that collects whole liquid blood samples.
Gracieuse: Tasso Inc.
HIMS and HIS users will receive a blood lancet provided by the Tasso home diagnostic test company. The Lancet is a single -use device that collects whole liquid blood samples and is eliminated for premature use by the FDA.
Users tie the device at their top of the arm and press a button that triggers the Lancet to prick the skin and draw a small amount of blood collected in a microtube.
Platform providers will use the information collected as part of the determination of a treatment plan for patients.
Hims & Hers said it would use blood test data – with deleted patient identities – to accelerate its development of health care powered by artificial intelligence.
Clarification: This story has been updated to reflect that the new test services will help the company’s perimenopausal care.